Alzheimer's Blood Tests Move Closer to Primary Care
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Traditional Alzheimer's diagnosis has relied on brain scans, spinal taps, or cognitive tests administered by behavioral neurologists, which the source describes as burdensome and constrained by limited specialist capacity.
- Research at the Alzheimer's Association International Conference (AAIC) in London indicated the field is moving toward more accessible testing and more nuanced results that go beyond a simple positive-or-negative Alzheimer's diagnosis.
- Blood-based biomarker tests for Alzheimer's have started to come onto the market, with the Alzheimer's Association beginning to issue guidelines for how doctors should use them.
- One study at the conference examined whether these blood-based biomarker tests could be deployed in primary care settings rather than limited to specialist use.
- Alzheimer's experts say expanding who can diagnose the condition is crucial because new treatments are more beneficial the earlier they can be administered to patients.
- Wait times for neurologists can extend for months, if not over a year, underscoring the access gap that earlier diagnosis in primary care could help address.
Why it matters: With neurologist wait times stretching months to over a year and new Alzheimer's treatments working better when given early, moving blood-based diagnostic tests into primary care settings targets the exact bottleneck that has kept patients from reaching treatment in the optimal window. Primary care physicians — who see most patients first — would gain a triage tool that reshapes when and where Alzheimer's gets diagnosed.
